Stefanos Pantagis, MD
Geriatric Medicine · Hackensack, NJNPI 1235212879
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 93.2% of the total across 114 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 28 manufacturers, the largest accounting for just 13.7% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2019 at $723 and has fallen 95.8% since, to $31 in 2025.
Across 114 payments — averaging $17.66 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amarin Pharma, Inc.$276
- Acadia Pharmaceuticals Inc$211
- Otsuka America Pharmaceutical, Inc.$199
- Medtronic$149
- Eisai Inc.$123
- Novartis$117
- plus $938 from 22 others
What the payments were for
- Speaking & faculty fees$251%
- Food & beverage$1,87693%
- Education$1126%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Valiant Captivia$149
- Vascepa$125
- Leqembi$123
- NUPLAZID$121
- REXULTI$120
How this compares
$2,013 in reported general payments places this provider in the 80th percentile of 165 geriatric medicine providers in New Jersey.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 951 | $474,234 |
| Penicillamine | 13 | $182,912 |
| XareltoRivaroxaban | 251 | $124,215 |
| JardianceEmpagliflozin | 146 | $79,596 |
| NuplazidPimavanserin Tartrate | 13 | $68,505 |
| MyrbetriqMirabegron | 133 | $65,261 |
| EntrestoSacubitril/Valsartan | 89 | $53,752 |
| JanuviaSitagliptin Phosphate | 95 | $53,209 |
| OzempicSemaglutide | 37 | $38,096 |
| LinzessLinaclotide | 54 | $31,419 |
| RexultiBrexpiprazole | 23 | $27,726 |
| SantylCollagenase Clostridium Hist. | 17 | $26,455 |
| Atorvastatin Calcium | 1,465 | $26,420 |
| FarxigaDapagliflozin Propanediol | 41 | $24,350 |
| Risperidone ErRisperidone Microspheres | 17 | $23,745 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $56 | $474,234951 claims |
| Johnson & JohnsonXarelto | $86 | $124,215251 claims |
| Boehringer IngelheimJardiance | $26 | $79,596146 claims |
| Acadia Pharmaceuticals IncNuplazid | $211 | $68,50513 claims |
| Astellas Pharma US IncMyrbetriq | $13 | $65,261133 claims |
| NovartisEntresto | $117 | $53,75289 claims |
| MerckJanuvia | $41 | $53,20995 claims |
| AstraZenecaFarxiga, Brilinta | $87 | $40,177107 claims |
| Novo NordiskOzempic | $40 | $38,09637 claims |
| Otsuka America Pharmaceutical, Inc.Rexulti | $199 | $27,72623 claims |
| Sumitomo Pharma America, Inc.Gemtesa | $54 | $21,94646 claims |
| Lilly USA, LLCMounjaro | $17 | $21,68720 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 165 geriatric medicine providers in New Jersey.
Other geriatric medicine in Hackensack
- Sarita RastogiHackensack$7K
- Kalpana CheetiHackensack$2K
- Albert RiddleHaworth$524K
- Gamil MakarClifton$82K
- Joshua Shua HaimManchester$45K
- Pradip ShahWest Caldwell$27K
- Gregorio GuillenPerth Amboy$8K
- Ketankumar VaidyaEdison$8K
- Cheng-An MaoClifton$8K
- Theresa RedlingLivingston$7K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.